Cerdulatinib is under clinical development by Alexion Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cerdulatinib’s likelihood of approval (LoA) and phase transition for B-Cell Chronic Lymphocytic Leukemia took place on 29 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cerdulatinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cerdulatinib overview

Cerdulatinib (PRT-2070, PRT-062070, DMVT-502) is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, B-cell non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma and mantle cell lymphoma), arthritis, cutaneous T-cell lymphoma, Waldenstrom's macroglobulinemia, atopic dermatitis, vitiligo and inflammatory skin diseases, peripheral T-cell lymphoma including angioimmunoblastic T cell lymphoma, follicular T-cell lymphoma, nodal lymphomas of T follicular helper, anaplastic large cell lymphoma, hepatosplenic T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, angioimmunoblastic T cell lymphoma and extranodal NK/T-cell lymphoma. The drug candidate is administered through oral, topical and ophthalmic routes. PRT-062070 is a dual SYK-JAK inhibitor. It blocks the B-cell receptor pathway via Syk and cytokine pathways via JAK 1, 3 and Tyk 2.

The drug candidate was also under development for the treatment of various ophthalmic indications and alopecia areata, anaplastic large cell lymphoma.

Alexion Pharmaceuticals overview

Alexion Pharmaceuticals (Alexion) discovers, develops, and markets therapies based on complement biology and inhibition for rare diseases. Deep understanding of rare disease enables the company to innovate and enter new areas, where there is a great unmet medical need. The company’s portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody positive patients. The company also offers novel enzyme replacement therapies for patients with lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), and ultra-rare metabolic disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Quick View Cerdulatinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Cerdulatinib
Administration Pathway
  • Ophthalmic
  • Oral
  • Topical
Therapeutic Areas
  • Dermatology
  • Musculoskeletal Disorders
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.